Clinical Trial

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trials evaluates how well different types of phytocannabinoids (cannabidiol \[CBD\] versus tetrahydrocannabinol \[THC\] and CBD formulation \[THC:CBD\]) work to reduce chronic chemotherapy-induced peripheral neuropathy among breast and colon cancer survivors. Chemotherapy induced peripheral neuropathy is a set of symptoms that includes pain, tingling, numbness and motor weakness caused by certain types of chemotherapy treatment. Phytocannabinoids are compounds made by the cannabis plant, such as THC and CBD, that have been found to be an effective treatment for chronic pain. Phytocannabinoids may be effective in reducing chronic chemotherapy-induced peripheral neuropathy symptoms in patients treated for breast or colon cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-12-11; most recent amendment 2025-12-03.
Status change: Not Yet Recruiting → Recruiting 2025-07-07
Trial Details
NCT Number NCT06731894
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
Enrollment 120 participants
Start Date 2025-10-03
Primary Completion 2028-01-07 (estimated)
Study Completion 2028-01-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-05